Back to Results
First PageMeta Content
Pharmacology / Amgen / Etanercept / Wyeth / Rheumatoid arthritis / Tumor necrosis factor-alpha / Disease-modifying antirheumatic drug / Placebo / Biologic / Medicine / Immunosuppressants / Biology


Open Document

File Size: 2,23 MB

Share Result on Facebook

City

Rockville / Lincoln / /

Company

Immunex Corporation / /

Event

FDA Phase / /

Facility

American College of Rheumatology / Rockville Pike / /

IndustryTerm

proposed introductory advertising / Final printed advertising / colorless solution / /

MedicalCondition

adult rheumatoid arthritis / tumor necrosis factor receptor / polyarticular-course juvenile rheumatoid arthritis / inflammatory processes / ankylosing spondylitis / RA psoriatic arthritis / arthritis / rheumatoid arthritis / RA disease / tumor necrosis factor / juvenile rheumatoid arthritis / normal inflammatory and immune responses / inflammation / psoriatic arthritis / /

Organization

Drug Evaluation and Research Division of Drug Marketing / Advertising and Communication / Therapeutic Biological Internal Medicine Products Office / Food and Drug Administration / ID SC / American College of Rheumatology / DEPARTMENT OF HEALTH / office of Therapeutics Research / Center for Drug Evaluation / Center for Biologics Evaluation and Research / r~ WA Director Division / Pharmacokinetics After administration / /

Person

Douglas Hunt / /

Position

Physician global assessment / Director / Amgen Regulatory Affairs One Amgen Center Drive Mail Stop 24Thousand Oaks / Ill PIB\MP / Major / CLINICAL PHARMACOLOGY General / /

Product

SC / ENBREL / sulfasalazine / MTX tablets / Bacteriostatic Water for Injection / azathioprine / mannitol / Etanercept / HFM-219 / /

ProvinceOrState

Maryland / Illinois / California / /

Technology

alpha / Pharmacokinetics / http / html / recombinant DNA technology / PDF / /

SocialTag